Member Info for Taff8

This is our product?? Is the $25m for us??

Imtresting

March 2020 16:24
* U.S.-listed shares of Tiziana Life Sciences plc surge as much as 281.2% to a record high of $7.70
* U.K.-based Tiziana says its TZLS-501 could be a potential treatment for patients infected with coronavirus (COVID-19) who are at a risk of respiratory failure...
* Tests have already shown that treatment rapidly depletes circulating levels of IL-6 in the blood, co says in a statement
* An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness
* Co is expediting development of TZLS-501 with Swiss biotechnology firm Novimmune SA
* Co's U.S.-listed shares were among the top percentage gainers across U.S. exchanges with over 8.6 mln shares exchanging hands in its busiest day ever
* Co's London-listed shares jump 150% to their highest level in 10 months
* U.S.-listed shares have nearly doubled in value YTD

Seller out and £1 before news

Under the reader multibag coming

I'm in here@39p and Sng@48p hopefully both can multibag over the next few weeks, you make your own luck

First bought@27p sold@45,then bought@53o and sold@72p (early wed morning) bought back fri@48p,hopefully can stick until £2 this time.

Is this ours??

Over the weekend,potential is mind blowing with current situation

Investors won't want to be out over the weekend

Going back up??

Thanks guys,

Fastest way to lose money no patience, sit and wait won't be too long

New York/London, March 11, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in 2017.

News due Monday

Group Revenue was £491m, up 2% on last year (H1 19: £480m) reflecting the solid performance of both the Roadside and Insurance divisions

Us opens 1.30

This going mental

10bagger over 5yrs easy

Coming here very soon